natgillin/translations-raw huggingface dataset:
Overall the major clearance route is metabolism, with minor contributions from renal and biliary elimination.
Ukupno gledajući glavni put izlučivanja je metabolizam, uz manji značaj izlučivanja putem bubrega i žuči.
The tablets are breakable along the score line.
Tablete se mogu prelomiti po razdjelnoj liniji.
Papilloma was considered treatment related, but not dose related.
Smatra se da su papilomi vezani uz liječenje, ali ne i uz dozu.
The clinical relevance of these observed effects for animals vaccinated while being administered oclacitinib (in accordance with the recommended dosing regimen) is unclear.
Klinički značaj navedenih učinaka kod životinja koje su cijepljene dok su bile tretirane oclacitinibom (sukladno sa propisanim količinama koje se primjenjuju) je nejasan.
Given the potential for effects on certain clinicopathological parameters (see section 4.6), periodic monitoring with complete blood counts and serum biochemistry is recommended when dogs are on long-term treatment.
Zbog potencijalnih učinaka na neke kliničko patološke parametre (vidi odjeljak 4.6), preporučeno je praćenje cjelokupne krvne slike i biokemije seruma kod pasa koji su podvrgnuti dugotrajnom liječenju.
Oclacitinib is metabolised in the dog to multiple metabolites.
Oklacitinib se kod pasa metabolizira u više metabolita.
16 mg oclacitinib (as oclacitinib maleate) For the full list of excipients, see section 6.1.
16 mg oklacitiniba (u obliku oklacitinib maleata) Potpuni popis pomoćnih tvari vidi u odjeljku 6.1.
Lymphadenopathy of peripheral nodes was noted in all groups, increasing in frequency with increasing dose, and was frequently associated with interdigital furunculosis.
Limfadenopatija perifernih čvorova je uočena u svim grupama, učestalost se povećava sa povećanjem doze, i često je povezana s interdigitalnim furunkulozama.
Given the potential for effects on certain clinicopathological parameters (see section 6), periodic monitoring with complete blood counts and serum biochemistry is recommended when dogs are on long-term treatment.
Zbog potencijalnih učinaka na neke kliničko patološke parametre (vidi odjeljak 6), preporučeno je praćenje cjelokupne krvne slike i biokemije seruma kod pasa koji su podvrgnuti dugotrajnom liječenju.
For maintenance therapy (after the initial 14 days of treatment), the same dose (0.4 to 0.6 mg oclacitinib/kg bodyweight) should then be administered only once a day.
Kao potporna terapija (nakon prvih 14 dana terapije), ista doza (0,4 do 0,6 mg oklacitiniba/kg tjelesne težine) se primjenjuje jednom dnevno.
All tablets strengths are packaged in either aluminium/PVC/Aclar blisters (each strip containing 10 film-coated tablets) packed into an outer cardboard box, or white HDPE plastic bottle with child resistant closure.
Sve jačine tableta su pakirane u aluminijske/PVC/Aclar blistere (svaka traka sadrži 10 filmom obloženih tableta).
Film-coated tablets
OBLIK Filmom obložena tableta
Do not use in dogs with evidence of immune suppression, such as hyperadrenocorticism, or with evidence of progressive malignant neoplasia as the active substance has not been evaluated in these cases.
Ne primjenjivati kod pasa s potvrđenom imunosupresijom, kao što je hiperadrenokorticizam ili kod pasa sa potvrđenom progresivnom malignom neoplazijom stoga što djelatna tvar nije procijenjena u takvim slučajevima.
polydipsia, lymphadenopathy, nausea, increased appetite and aggression have been observed commonly.
pododermatitis, lipom, polidipsija, limfadenopatija, mučnina, pojačani apetit i agresija.
The impact of oclacitinib administration on vaccination with modified live vaccines, canine parvovirus (CPV), canine distemper virus (CDV) and canine parainfluenza (CPI) and inactivated rabies vaccine (RV), on 16 week old vaccine naïve puppies has been studied.
Učinak primjene oklacitiniba na cijepljenje s modificiranim živim cjepivima, parvovirusom pasa (CPV), virusom štenećaka (CDV) i parainfluencom pasa (CPI) i s inaktiviranim cjepivom bjesnoće (RV), kod 16 tjedana starih štenaca (nikad prije liječenih) je praćen u studiji.
Each film-coated tablet contains 3.6 mg, 5.4 mg or 16 mg oclacitinib (as oclacitinib maleate).
Svaka filmom obložena tableta sadrži 3,6 mg, 5,4 mg ili 16 mg oklacitiniba u obliku oklacitinib maleata.
Any remaining half tablet should be stored in the bottle and discarded if not used within 3 days.
Svaku preostalu polovicu tablete treba vratiti u bocu i baciti ako se ne iskoristi unutar 3 dana.
Clinical observations that were considered likely to be related to oclacitinib treatment included: alopecia (local), papilloma, dermatitis, erythema, abrasions and scabbing/crusts, interdigital "cysts", and oedema of the feet.
Klinička opažanja za koja se smatra da su povezana sa terapijom oclacitinibom uključuju: alopecije (lokalne), papilome, dermatitis, eriteme, abrazije i kraste, interdigitalne „ciste“ i edeme ekstremiteta.
EU/2/13/154/001 (1 x 20 tablets, 3.6 mg) EU/2/13/154/007 (1 x 50 tablets, 3.6 mg) EU/2/13/154/002 (1 x 100 tablets, 3.6 mg) EU/2/13/154/010 (20 tablets, 3.6 mg) EU/2/13/154/011 (50 tablets, 3.6 mg) EU/2/13/154/012 (100 tablets, 3.6 mg) EU/2/13/154/003 (1 x 20 tablets, 5.4 mg) EU/2/13/154/008 (1 x 50 tablets, 5.4 mg) EU/2/13/154/004 (1 x 100 tablets, 5.4 mg) EU/2/13/154/013 (20 tablets, 5.4 mg) EU/2/13/154/014 (50 tablets, 5.4 mg) EU/2/13/154/015 (100 tablets, 5.4 mg) EU/2/13/154/005 (1 x 20 tablets, 16 mg) EU/2/13/154/009 (1 x 50 tablets, 16 mg) EU/2/13/154/006 (1 x 100 tablets, 16 mg) EU/2/13/154/016 (20 tablets, 16 mg) EU/2/13/154/017 (50 tablets, 16 mg) EU/2/13/154/018 (100 tablets, 16 mg)
EU/2/13/154/001 (1 x 20 tableta, 3,6 mg) EU/2/13/154/007 (1 x 50 tableta, 3,6 mg) EU/2/13/154/002 (1 x 100 tableta, 3,6 mg) EU/2/13/154/010 (20 tableta, 3,6 mg) EU/2/13/154/011 (50 tableta, 3,6 mg) EU/2/13/154/012 (100 tableta, 3,6 mg) EU/2/13/154/003 (1 x 20 tableta, 5,4 mg) EU/2/13/154/008 (1 x 50 tableta, 5,4 mg) EU/2/13/154/004 (1 x 100 tableta, 5,4 mg) EU/2/13/154/013 (20 tableta, 5,4 mg) EU/2/13/154/014 (50 tableta, 5,4 mg) EU/2/13/154/015 (100 tableta, 5,4 mg) EU/2/13/154/005 (1 x 20 tableta, 16 mg) EU/2/13/154/009 (1 x 50 tableta, 16 mg) EU/2/13/154/006 (1 x 100 tableta, 16 mg) EU/2/13/154/016 (20 tableta, 16 mg) EU/2/13/154/017 (50 tableta, 16 mg) EU/2/13/154/018 (100 tableta, 16 mg)
No accumulation was observed in the blood of dogs treated for 6 months with oclacitinib.
Nije uočeno nakupljanje u krvi pasa nakon šestomjesečnog davanja oklacitiniba.
The recommended initial dose is 0.4 to 0.6 mg oclacitinib/kg bodyweight, administered orally, twice daily for up to 14 days.
Preporučena početna doza je 0,4 do 0,6 mg oklacitiniba/kg tjelesne težine, primijenjena peroralno, dva puta dnevno kroz najviše 14 dana.
The frequency of adverse reactions is defined using the following convention: - very common (more than 1 in 10 animals treated displaying adverse reaction(s)) - common (more than 1 but less than 10 animals in 100 animals treated) - uncommon (more than 1 but less than 10 animals in 1,000 animals treated) - rare (more than 1 but less than 10 animals in 10,000 animals treated) - very rare (less than 1 animal in 10,000 animals treated, including isolated reports).
- rijetke (više od 1 ali manje od 10 životinja na 10.000 tretiranih životinja).
In case of accidental ingestion, seek medical advice immediately and show the package leaflet or label to the physician.
U slučaju da se nehotice proguta, odmah potražiti pomoć liječnika i pokazati mu uputu o VMP ili etiketu.
Apoquel 16 mg tablets for dogs.
Apoquel 16 mg tablete za pse.
Dosage and treatment schedule:
Doziranje i raspored primjene:
After day 16, the following adverse reactions have been observed: - pyoderma and non-specified dermal lumps have been observed very commonly; - otitis, vomiting, diarrhoea, histiocytoma, cystitis, yeast skin infections, pododermatitis, lipoma,
Nakon 16. dana, uočene su sljedeće nuspojave: - vrlo često su primijećene pioderma i nespecifične kožne kvržice, - često su primijećeni otitis, histiocitom, cistitis, kožne infekcije uzrokovane kvascima,
Lack or loss of appetite (Anorexia)
Povraćanje Pomanjkanje ili gubitak apetita (Anoreksija) Novonastale kutane ili subkutane kvržice Slabost (Letargija) Pojačana žeđ (Polidipsija)
The recommended initial dose of Apoquel tablets to be given to the dog is to achieve 0.4 to 0.6 mg oclacitinib/kg bodyweight, administered orally, twice daily for up to 14 days.
Preporučena početna doza Apoquel tableta koje se daju psu da bi se postigla 0,4 do 0,6 mg oklacitiniba/kg tjelesne težine, primijenjena peroralno, je dva puta dnevno kroz najviše 14 dana.
EU/2/13/154/010 (20 tablets, 3.6 mg) EU/2/13/154/011 (50 tablets, 3.6 mg) EU/2/13/154/012 (100 tablets, 3.6 mg) EU/2/13/154/013 (20 tablets, 5.4 mg) EU/2/13/154/014 (50 tablets, 5.4 mg) EU/2/13/154/015 (100 tablets, 5.4 mg) EU/2/13/154/016 (20 tablets, 16 mg) EU/2/13/154/017 (50 tablets, 16 mg) EU/2/13/154/018 (100 tablets, 16 mg)
EU/2/13/154/010 (20 tableta, 3,6 mg) EU/2/13/154/011 (50 tableta, 3,6 mg) EU/2/13/154/012 (100 tableta, 3,6 mg) EU/2/13/154/013 (20 tableta, 5,4 mg) EU/2/13/154/014 (50 tableta, 5,4 mg) EU/2/13/154/015 (100 tableta, 5,4 mg) EU/2/13/154/016 (20 tableta, 16 mg) EU/2/13/154/017 (50 tableta, 16 mg) EU/2/13/154/018 (100 tableta, 16 mg)
Apoquel (n=152)
(n=152)
EU/2/13/154/001 (1 x 20 tablets, 3.6 mg) EU/2/13/154/007 (1 x 50 tablets, 3.6 mg) EU/2/13/154/002 (1 x 100 tablets, 3.6 mg) EU/2/13/154/003 (1 x 20 tablets, 5.4 mg) EU/2/13/154/008 (1 x 50 tablets, 5.4 mg) EU/2/13/154/004 (1 x 100 tablets, 5.4 mg) EU/2/13/154/005 (1 x 20 tablets, 16 mg) EU/2/13/154/009 (1 x 50 tablets, 16 mg) EU/2/13/154/006 (1 x 100 tablets, 16 mg)
EU/2/13/154/001 (1 x 20 tableta, 3,6 mg) EU/2/13/154/007 (1 x 50 tableta, 3,6 mg) EU/2/13/154/002 (1 x 100 tableta, 3,6 mg) EU/2/13/154/003 (1 x 20 tableta, 5,4 mg) EU/2/13/154/008 (1 x 50 tableta, 5,4 mg) EU/2/13/154/004 (1 x 100 tableta, 5,4 mg) EU/2/13/154/005 (1 x 20 tableta, 16 mg) EU/2/13/154/009 (1 x 50 tableta, 16 mg) EU/2/13/154/006 (1 x 100 tableta, 16 mg)
No drug interactions were observed in field studies where oclacitinib was administered concomitantly with veterinary medicinal products such as endo- and ectoparasiticides, antimicrobials and antiinflammatories.
U terenskim ispitivanjima nisu uočene interakcije kada je oklacitinib primjenjivan usporedno sa drugim VMP, kao što su endo- ili ektoparazitici, antibiotici i protuupalni veterinarsko-medicinski proizvodi.
ANNEX I 0BSUMMARY OF PRODUCT CHARACTERISTICS
0BSAŽETAK OPISA SVOJSTAVA
For maintenance therapy, the same dose (0.4 to 0.6 mg oclacitinib/kg bodyweight) should then be administered only once a day.
Kao potporna terapija, ista doza (0,4 do 0,6 mg oklacitiniba/kg tjelesne težine) se primjenjuje jednom dnevno.
oclacitinib
oklacitinib
Apoquel (n=216)
(n=216)
Any remaining half tablet should be stored in the blister and discarded if not used within 3 days.
Svaku preostalu polovicu tablete treba vratiti u blister i baciti ako se ne iskoristi unutar 3 dana.
Apoquel 3.6 mg tablets for dogs.
Apoquel 3,6 mg tablete za pse.
The prandial state of the dog does not significantly affect the rate or extent of its absorption.
Uzimanje na tašte ili nakon obroka nema značajan učinak na brzinu i stupanj resorpcije.
Apoquel 5.4 mg tablets for dogs.
Apoquel 5,4 mg tablete za pse.
Strength and number of tablets to be administered: Apoquel 3.6 mg tablets Apoquel 5.4 mg tablets Apoquel 16 mg tablets
Jačina i broj tableta koje se primjenjuju: Apoquel 3.6 mg tablete Apoquel 5.4 mg tablete Apoquel 16 mg tablete
When treating pruritus associated with allergic dermatitis with oclacitinib, investigate and treat any underlying causes (e.g., flea allergic dermatitis, contact dermatitis, food hypersensitivity).
Kada se oclacitinibom liječi svrbež povezan sa alergijskim dermatitisom treba ispitati i tretirati osnovni uzrok svrbeža (npr. alergijski dermatitis uzrokovan buhama, kontaktni dermatitis, preosjetljivost na hranu).
Dermatitis lesions were mostly secondary to the development of interdigital furunculosis on one or more feet during the study, with the number and frequency of observations increasing with increasing dose.
Za vrijeme provođenja studije uočeno je da su lezije uzrokovane dermatitisom uglavnom sekundarne pri stvaranju interdigitalnih furunkuloza na jednom ili više ekstremiteta, s time da se broj i učestalost lezija povećava sa povećavanjem doze.
20 tablets 50 tablets 100 tablets
100 tableta
New cutaneous or subcutaneous lumps Lethargy
Povraćanje Anoreksija Novonastale kutane ili supkutane kvržice Letargija
16 mg oclacitinib per tablet (as oclacitinib maleate).
16 mg oklacitiniba po tableti (u obliku oklacitinib maleata).
3.6 mg oclacitinib (as oclacitinib maleate)
3,6 mg oklacitiniba (u obliku oklacitinib maleata)
PARTICULARS TO APPEAR ON THE OUTER PACKAGE CARDBOARD CARTON for Blister
KARTONSKA KUTIJA za blister
PARTICULARS TO APPEAR ON THE IMMEDIATE PACKAGE LABEL for Bottle
PODACI KOJI SE MORAJU NALAZITI NA UNUTARNJEM PAKOVANJU
5.4 mg oclacitinib (as oclacitinib maleate)
5,4 mg oklacitiniba (u obliku oklacitinib maleata)
5.4 mg oclacitinib per tablet (as oclacitinib maleate).
5,4 mg oklacitiniba po tableti (u obliku oklacitinib maleata).
Apoquel 3.6 mg film-coated tablets for dogs Apoquel 5.4 mg film-coated tablets for dogs Apoquel 16 mg film-coated tablets for dogs oclacitinib
Apoquel 3,6 mg filmom obložena tableta za pse Apoquel 5,4 mg filmom obložena tableta za pse Apoquel 16 mg filmom obložena tableta za pse oklacitinib
PACKAGE LEAFLET: Apoquel 3.6 mg film-coated tablets for dogs Apoquel 5.4 mg film-coated tablets for dogs Apoquel 16 mg film-coated tablets for dogs
UPUTA O VMP: Apoquel 3,6 mg filmom obložena tableta za pse Apoquel 5,4 mg filmom obložena tableta za pse Apoquel 16 mg filmom obložena tableta za pse
Diarrhoea
FARMACEUTSKI
Vomiting
Proljev
Name and address of the manufacturers responsible for batch release
PROIZVOĐAČI ODGOVORNI ZA PUŠTANJE SERIJE U PROMET Naziv i adresa proizvođača odgovornogih za puštanje serije u promet Pfizer Italia S.R.L.
Blister (PVC/PVDC) 63 (3 x 21) tablets
20 mg filmom obložena tableta kroz usta blister (PVC/PVDC) 63 (3 x 21) tablete
Oral use
Doza
MA (EU) number (Invented) name Strength Pharmaceutical Form Route of Administration
Broj (EU) odobrenja (Zaštićeno)ime
Film-coated tablet
Farmaceutski oblik Put primjene
What you need
Što će Vam trebati
You will need to use a new syringe if:
Morat ćete koristiti novu štrcaljku ako:
This is especially important for infants and young children.
Ovo je posebno važno kod dojenčadi i male djece.
Use within 2 hours.
Uzmite unutar 2 sata.
− if you are currently taking any of the following medicines:
− ako trenutno uzimate bilo koji od ovih lijekova:
Norvir should be taken every day to help control your HIV, no matter how much better you feel.
Norvir morate uzimati svaki dan kako bi se kontrolirao HIV, bez obzira na to koliko se bolje osjećate.
You may need more than 1 sachet for each dose.
Možda će Vam trebati više od 1 vrećice za svaku dozu.
Check the syringe before each use
Provjerite štrcaljku prije svake upotrebe
Any mixing outside the recommendations is the responsibility of the health care professional or the user.
Svako miješanje koje se ne izvodi prema preporuci je odgovornost zdravstvenog radnika ili korisnika.
If there are still lumps, keep shaking until they have all gone.
Ako još uvijek ima grudica, tresite dok ne nestanu.
What Norvir is and what it is used for
Što je Norvir i za što se koristi
Norvir can be used during pregnancy if clinically needed.
Norvir se može primjenjivati tijekom trudnoće ako je to klinički potrebno.
Follow the instructions below:
Slijedite donje upute:
b. Each 0.2 ml is shown as a smaller line between the numbers.
b. Svakih 0,2 ml je prikazano kao kraća linija između brojeva.
†In some instances, the volumes and/or doses have been adjusted to ensure the recommended final dose and dosing volume.
†U nekim slučajevima su volumeni i/ili doze prilagođeni kako bi se osigurala preporučena konačna doza i volumen doziranja.
Prepare only one dose at a time using the correct number of sachets.
Pripremite samo jednu dozu odjednom koristeći točan broj vrećica.
Contents of the pack and other information What Norvir contains
Sadržaj pakiranja i druge informacije Što Norvir sadrži
If you need to use more than one sachet, repeat the process from the beginning.
Ako trebate primijeniti više od jedne vrećice, ponovite postupak od početka.
Following mixing with food or liquid as described in section 4.2: consume within 2 hours.
Nakon miješanja s hranom ili tekućinom kao što je opisano u dijelu 4.2: upotrijebiti unutar 2 sata.
(µg•h/ml) t½ (h)
(mikrogram•h/ml) t½ (h)
These are listed earlier in section 2, under ‘Do not take Norvir'.
Oni su navedeni ranije u dijelu 2 u odjeljku „Nemojte uzimati Norvir“.
c. Check if the sachet is empty.
Provjerite je li vrećica prazna.
When you travel or need to stay in the hospital, make sure you have enough Norvir to last until you can get a new supply.
Kada putujete ili morate ostati u bolnici, uvijek pazite da imate dovoljno lijeka Norvir do pribavljanja nove zalihe.
Date of first authorisation: 26 August 1996 Date of latest renewal: 26 August 2006
Datum posljednje obnove odobrenja: 26. kolovoza 2006.
When mixing the powder with food or liquid, be sure to take the whole dose within 2 hours.
Kada pomiješate prašak s hranom ili tekućinom, pobrinite se da uzmete cijelu dozu unutar 2 sata.
Norvir did not appear to increase the chance of developing birth defects compared to the general population.
Čini se da Norvir ne povećava izglede za pojavu porođajnih nedostataka u usporedbi s općom populacijom.
Norvir may experience changes in the electrocardiogram (ECG).
Norvir mogu se javiti promjene elektrokardiograma (EKG).
• Once the powder is mixed, the prepared suspension should be used within 2 hours.
• Nakon što je prašak pomiješan, pripremljena suspenzija se mora primijeniti unutar 2 sata.
Effects on the Electrocardiogram
Učinci na elektrokardiogram
• the syringe is damaged or leaking.
• štrcaljka je oštećena ili curi.
• If the syringe breaks or becomes hard to use, the syringe should be thrown away and the new one used.
• Ako se štrcaljka potrga ili ju postane teško koristiti, štrcaljka se treba baciti i koristiti nova.
- Symptoms of infection - inform your doctor immediately.
Simptomi infekcije - Odmah o tome obavijestite svog liječnika.
Always keep enough Norvir on hand so you don't run out.
Uvijek imajte pri ruci dovoljno lijeka Norvir, tako da Vam ne ponestane.
c. Give the patient the full dose within 2 hours of opening the sachet.
c. Dajte bolesniku cijelu dozu unutar 2 sata od otvaranja vrećice.
What Norvir looks like and contents of the pack
Kako Norvir izgleda i sadržaj pakiranja
To avoid transmitting the infection, mothers with HIV must not breast feed their babies.
Da bi se izbjegao prijenos infekcije, majke s HIV-om ne smiju dojiti djecu.
Be careful not to pull the plunger out.
Pripazite da ne povučete klip van.
Talk to your doctor before taking Norvir.
Razgovarajte sa svojim liječnikom prije uzimanja lijeka Norvir.
b. Tap the syringe with your other hand.
Lupkajte štrcaljku s drugom rukom.
− if you have severe liver disease.
− ako imate tešku bolest jetre.
If you have any further questions about Norvir (ritonavir) or the other medicines prescribed, please ask your doctor or pharmacist.
Imate li dodatnih pitanja o lijeku Norvir (ritonavir) ili o drugim lijekovima koji su Vam propisani, molimo obratite se svome liječniku ili ljekarniku.
c. If you push out too much liquid, start again from Step 7.
Ako istisnete previše tekućine, ponovo započnite s korakom 7.
Like all medicines, Norvir can cause side effects, although not everybody gets them.
Kao i svi lijekovi, i Norvir može uzrokovati nuspojave iako se one neće javiti kod svakoga.
AbbVie Biofarmacevtska družba d.o.o.
AbbVie Biofarmacevtska družbad.o.o.
Other medicines and Norvir
Drugi lijekovi i Norvir
If you do need more than 1 sachet, repeat all the steps with each sachet.
Ako Vam je potrebno više od 1 vrećice, ponovite korake sa svakom vrećicom.
Norvir tablets should be taken with food.
Norvir tablete se moraju uzimati s hranom.
Feed serving to patient.
Poslužite hranu bolesniku.
• Pour the entire contents of 1 sachet (100 mg) into the mixing cup.
• Uspite cijeli sadržaj 1 vrećice (100 mg) u čašu za miješanje.
Be careful not to spill any powder outside of the mixing cup (see Figure 6).
Pripazite da ne prospete prašak izvan čaše za miješanje (pogledajte sliku 6).
Amlodipine, diltiazem, nifedipine
Amlodipin, diltiazem, nifedipin
Warfarin S-Warfarin R-Warfarin
Varfarin S-varfarin R-varfarin
Some patients taking
nekih bolesnika koji uzimaju
ENTIRE serving must be eaten (see Figure 6).
Mora se pojesti CIJELI obrok (pogledajte sliku 6).
− ergonovine, methylergonovine (used to stop excessive bleeding that may occur following childbirth or an abortion);
− ergonovin, metilergonovin (koriste se za zaustavljanje pretjeranog krvarenja koje može nastupiti nakon porođaja ili pobačaja);
Medication error
Medikacijske pogreške
Special attention should be given to the accurate calculation of the dose of Norvir, transcription of the medication order, dispensing information and dosing instructions to minimise the risk for medication errors and underdose.
Posebna se pozornost mora obratiti na točan izračun doze lijeka Norvir, propisivanje lijeka, davanje informacija pri izdavanju lijeka i upute o doziranju kako bi se minimalizirao rizik od medikacijskih pogrešaka i subdoziranja.
Your doctor may need to adjust the dose of digoxin and monitor you while you are taking digoxin and Norvir in order to avoid heart problems.
Liječnik će možda morati prilagoditi dozu digoksina i pratiti Vas za vrijeme dok uzimate digoksin i Norvir, kako bi se izbjegli problemi sa srcem.
There is a large amount of information on the use of ritonavir (the active ingredient in Norvir) during pregnancy.
Postoji mnogo podataka o primjeni ritonavira (djelatni sastojak lijeka Norvir) tijekom trudnoće.
These are listed earlier in section 2,
Oni su navedeni u dijelu 2, u odjeljku
Do not wash these in the dishwasher.
Ne perite u stroju za pranje posuđa.
There may be additional information in those leaflets about situations when Norvir should be avoided.
One mogu sadržavati dodatne informacije o situacijama u kojima Norvir trebate izbjegavati.
White, oval, debossed with [Abbott logo] and “NK”.
Bijela, ovalna, s utisnutim [Abbottov logo] i “NK”.
− You can still pass on HIV when taking this medicine, although the risk is lowered by effective antiretroviral therapy.
− HIV virus možete prenijeti čak i dok uzimate ovaj lijek, iako je tada rizik od prijenosa manji zbog učinkovite antiretrovirusne terapije.
Children (2 - 12 years of age) will start with a dose smaller than this and continue up to the maximum allowed for their size.
Liječenje djece (2 - 12 godina) počinje dozom manjom od te i ona se postupno povećava do one maksimalno dopuštene za njihovu težinu.
If you are currently taking any of these medicines, ask your doctor about switching to a different medicine while you are taking Norvir.
Ako trenutno uzimate bilo koji od tih lijekova, upitajte liječnika možete li uzimati drugi lijek za vrijeme dok uzimate Norvir.
Even if you feel better, do not stop taking Norvir without talking to your doctor.
Čak i ako se budete osjećali bolje, nemojte prestati uzimati Norvir a da se prethodno ne posavjetujete sa svojim liječnikom.
Body Surface Area (m2)
Površina tijela (m²)
d. Tap the syringe again.
d. Ponovo lupkajte štrcaljku.
All of the mixed soft food must be administered within 2 hours.
Sva pomiješana mekana hrana se mora primijeniti unutar 2 sata.
- If you have any other health concerns, discuss these with your doctor as soon as you can.
Ako ste na bilo koji način zabrinuti za svoje zdravlje, raspravite o tome sa svojim liječnikom čim budete mogli.
If you take more Norvir than you should
Ako uzmete više lijeka Norvir nego što ste trebali
f. If there are any large air bubbles, empty the liquid from the syringe into the mixing cup and start again from Step 7.
f. Ako primijetite veće mjehuriće zraka, ispraznite tekućinu iz štrcaljke u čašu za miješanje i ponovo započnite s korakom 7.
− amphetamine or amphetamine derivatives;
− amfetamin ili derivate amfetamina;